---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-055838"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:41:29.838034+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio CFO Henry Hagopian resigns; CEO Maria Maccecchini named interim CFO

## Summary
- Henry Hagopian stepped down as CFO effective April 30, 2024, to pursue other opportunities; no disagreement with company.
- CEO Maria Maccecchini appointed as interim principal financial officer effective May 1, 2024.
- Severance includes 2 months base salary ($62,500) plus $3,000 medical/dental reimbursement, paid as lump sum.
- Company accelerates vesting of 10,000 stock options and extends exercise period for certain options through Dec 31, 2024.
- Hagopian signed a separation agreement with a general release of claims and non-disparagement obligations.

## SEC filing metadata
- accession: 0001104659-24-055838
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465924055838/0001104659-24-055838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465924055838/tm2413238d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-055838
- JSON: https://secwatch.observer/filing/0001104659-24-055838.json
- Plain text: https://secwatch.observer/filing/0001104659-24-055838.txt

## Key facts
- Executive change
  Maria Maccecchini was appointed as interim principal financial officer at Annovis Bio, Inc..
  - Action: appointed
  - Role: interim principal financial officer
  source text: On May 1, 2024, the Board appointed Maria Maccecchini, the Company’s President and Chief Executive Officer, as the interim principal financial officer, effective immediately, in light of Mr. Hagopian’s departure.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477845/000110465924055838/0001104659-24-055838-index.htm
- Executive change
  Henry Hagopian departed as Chief Financial Officer at Annovis Bio, Inc..
  - Action: stepped down
  - Role: Chief Financial Officer
  source text: Effective as of the close of business on April 30, 2024, Henry Hagopian is no longer serving as the Chief Financial Officer and as principal financial officer of Annovis Bio, Inc. (the “Company”). Mr. Hagopian is stepping down from these positions to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477845/000110465924055838/0001104659-24-055838-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.